Benefits of Earlier Apremilast Initiation in Patients with Psoriasis and Limited Skin Involvement: Results from a Real-World Retrospective Study.

ABSTRACT:

Introduction

Many patients with psoriasis remain on topical therapy despite meeting criteria for systemic therapy. Our objective was to estimate the effect of earlier initiation of apremilast on attaining body surface area (BSA) treatment targets in patients with psoriasis in a real-world setting.

Methods

This retrospective cohort study conducted in the OM1 database analyzed patients with psoriasis and a BSA value between ≥ 1 and ≤ 10% (on index date) who had initiated apremilast or a topical treatment. Relative risks were used to compare achieved BSA targets across treatment groups. Confounding, selection bias, and missing data may have been present, but measures were taken to limit their impact.

Results

Of 3589 apremilast initiators, 2073 (57.8%) initiated early (≤ 

SUBMITTER: Armstrong A 

PROVIDER: S-EPMC12454763 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature